Oct 30 (Reuters) - Alnylam Pharmaceuticals Q3 adjusted operating income USD 476.193 million.
Q3 net product revenue USD 1,249.026 million vs. IBES estimate USD 946 million
Q3 operating income USD 367.982 million
Q3 adjusted net income USD 396.18 million
Q3 net income USD 251.084 million
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.